Member Info for Chan

Online gamer 888's management believes liability for a final settlement with the American authorities is somewhere between $40m and $100m, which is digestible with the company’s strong cash flow. 888 shares, up 3¼p to 150p, compare with the rumoured 135p offer from Ladbrokes and are up from last year’s low of 104 ¼p. The yield is a lowly 2.5% but strong cashflow justifies the multiple of 16 times 2008 holdings.

http://www.investegate.co.uk/Article.aspx?id=200804090701149366R

Hi GedW, interesting, I was reading up about BVC this evening not knowing you'd footprinted. I was checking out Gartmore Smaller Company's Top Ten Holdings and Batm Advanced is their largest Holding, so we're not alone in rating this Stock as valueable. I noted too that IQE is in there too. I agree with your view on future targets and have high hopes for this Company, it is quite unique. It's making steps fowards to former glory. Best wishes.

That's cool. Just to say the man's well thought of. PS RCG is looking better.

Keep' saved you a link re: Melvyn___http://www.bfhu.org/parent/263/___ It's safe!

.

.

MikaX, I know that , let's see if others realize it !

.

Absolutely. Good luck to you too.

Ok rthak. No, I remember this but don't have details.

In conversation yesterday evening it was agreed opinion that today the FTSE100 would probably drop and there was going to be profit taking and some retreating. It looks that way so far today. Out of our control sadly.

The recent Results on 28 February '08 were very good. The sentence "At this stage the outlook for 2008 is encouraging." is what one wants to hear.

I agree Major. Still hanging in, just nice to see a healthy return in the SP. More to come with Spirent I would say too.

Worth the wait,

http://www.investegate.co.uk/Article.aspx?id=200804080936458459R

On the Up

.

http://www.akersbiosciences.com/

Yesterday's News reads well between the lines. Operational Costs that created debts are now well down and this Company looks ready for better days._____Akers Biosciences Inc. said full year loss from operations narrowed on a surge in revenues and said it expects to build its core product line sales both domestically and abroad and bring forward new and mass market potential diagnostic products. The diagnostic testing products developer said loss from operations for the full year to December 31, 2007, was $1.74 million compared to $8.83 million a year earlier. Revenues for the period surged to $5.5 million from $1.4 million in the previous year due to the market penetration of its four core product lines. Akers added the acquisitions completed in 2006 and early 2007 have established it as a leading player in the portable alcohol breathalyzer business in the United States.